FFR – Medxy AI

Determining the Physiological Threshold for Angina (ORBITA-FIRE): A Double-Blind, Randomized, Placebo-Controlled Study

By MedXY 06/10/2026

ORBITA-FIRE shows that angina occurs at much lower, individualized FFR and RFR thresholds than standard ischemia cutoffs, and these thresholds rise with exercise intensity.

Cardiology news

Determining the Physiological Threshold for Angina (ORBITA-FIRE): A Double-Blind, Randomized, Placebo-Controlled Study

By MedXY 05/09/2026

ORBITA-FIRE study reveals personalized physiological thresholds for angina that are lower than current diagnostic standards. These thresholds vary during exercise and predict PCI treatment success, challenging universal ischemia-based guidelines.

Cardiology news

Bridging the Gap: Why In-Procedure QFR Variability May Explain the FAVOR III Europe Outcomes

By MedXY 02/04/2026

The REPEAT-QFR study reveals modest agreement between in-procedure and core laboratory quantitative flow ratio (QFR) measurements, suggesting that angiographic quality and user adherence significantly impact diagnostic accuracy.

Cardiology news

FFR-Guided PCI Demonstrates Decade-Long Superiority Over Medical Therapy in Stable Coronary Artery Disease

By MedXY 02/04/2026

An 11-year follow-up of the FAME 2 trial reveals that FFR-guided PCI significantly outperforms medical therapy alone in patients with hemodynamically significant stenoses, primarily by reducing urgent revascularizations, with a favorable win ratio of 1.25.

Cardiology news

FFR-Guided Revascularization Significantly Reduces 12-Month MACCE in TAVI Patients: The FAITAVI Trial

By MedXY 01/03/2026

The FAITAVI trial demonstrates that physiology-guided PCI using FFR significantly reduces major adverse cardiac events, particularly mortality, compared to angiography-guided PCI in elderly patients undergoing TAVI with intermediate coronary lesions.

Cardiology Clinical Updates news Specialties

High-Risk Plaques in Non-Culprit Lesions: Comparative Outcomes After NSTEMI and STEMI

By MedXY 08/16/2025

This study examines the morphology of high-risk plaques in non-culprit coronary lesions among NSTEMI and STEMI patients and their impact on clinical outcomes, suggesting comparable prevalence of high-risk features but differing plaque characteristics between these groups.